2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy

Authors :: Fabian Trillsch
Fabienne Schochter
Tjoung-Won Park-Simon
Alexander Reuß
Tanja Fehm
Pauline Wimberger
Holger Bronger
Barbara Schmalfeldt
Jalid Sehouli
Frederik Marmé
Florian Heitz
Sven Mahner
Michaela Fredrich
Stefanie Barth
James Stec
Michael Method
Philipp Harter
Source :: Ovarian cancer.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Tools